Uncategorized
calendar_month Nov 19, 2026

Dual Regulatory Wins for Sanofi Bring New Oral Gaucher Therapy and Upgraded Rabies Shot

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Sanofi SA’s (NASDAQ:SNY) Infilbray (venglustat), a novel, oral glucosylceramide synthase inhibitor (GCSi) that acts across the blood-brain barrier, for neurological manifestations of Type 3 Gaucher disease (GD3) in adults and pediatric patients.

GD3 is a rare lysosomal storage disorder that causes progressive systemic and neurologic decline, with central nervous system (CNS) manifestations.

LEAP2MONO Phase 3 Clinical Trial Results

The approval is based on positive data from the LEAP2MONO Phase 3 study, in which Infilbray demonstrated improvements in neurological manifestations over the enzyme replacement therapy (ERT) imiglucerase, with a global test of multiple neurological endpoints showing statistically significant superiority.

The LEAP2MONO phase 3 study evaluated the efficacy and safety of Infilbray in adults and pediatric patients aged 12 years and older with neurological manifestations of GD3 who previously achieved stabilization of their systemic manifestations with ERT.

The results demonstrated that patients receiving Infilbray achieved statistically significant improvements in certain neurological manifestations causing cognitive deficits and difficulty with coordination and balance.

European Commission Authorizes Sanofi’s VaxRabeo Rabies Vaccine

On Wednesday, the European Commission approved Sanofi’s VaxRabeo, an inactivated Wistar-strain rabies vaccine, for pre-exposure and post-exposure prophylaxis across all age groups.

Sanofi manufactures VaxRabeo using state-of-the-art Vero-cell technology. The company designed the shot to minimize allergic reaction risks while delivering improved thermostability and a longer shelf life than its current rabies vaccines.

Infected animals transmit the viral zoonotic disease primarily through saliva, most commonly via dog bites. World Health Organization estimates indicate rabies spans 150 countries and causes roughly 59,000 deaths worldwide each year, while about 29 million people receive post-exposure vaccination annually.

Clinical Trial Results Back EU Approval

A comprehensive clinical program comparing VaxRabeo with Sanofi’s standard-of-care shots, Verorab and Imovax Rabies, across all age groups and WHO-recommended schedules supports the European Union approval.

VaxRabeo matched existing vaccines in protective antibody levels, immunogenicity, and safety without significant safety concerns, while demonstrating high boostability from a booster dose given 12 or 24-36 months after pre-exposure vaccination.

SNY Price Action: Sanofi shares were down 2.08% at $46.14 during premarket trading on Thursday, according to Benzinga Pro data.

Photo via Shutterstock